Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Current Assets (2020 - 2025)

Caribou Biosciences (CRBU) has disclosed Current Assets for 6 consecutive years, with $145.2 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 33.8% to $145.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $145.2 million through Dec 2025, down 33.8% year-over-year, with the annual reading at $145.2 million for FY2025, 33.8% down from the prior year.
  • Current Assets for Q4 2025 was $145.2 million at Caribou Biosciences, down from $155.5 million in the prior quarter.
  • The five-year high for Current Assets was $449.0 million in Q3 2021, with the low at $143.0 million in Q2 2021.
  • Average Current Assets over 5 years is $274.3 million, with a median of $268.5 million recorded in 2023.
  • The sharpest move saw Current Assets surged 1509.45% in 2021, then crashed 35.26% in 2024.
  • Over 5 years, Current Assets stood at $391.2 million in 2021, then tumbled by 33.47% to $260.2 million in 2022, then soared by 30.2% to $338.8 million in 2023, then plummeted by 35.26% to $219.4 million in 2024, then plummeted by 33.8% to $145.2 million in 2025.
  • According to Business Quant data, Current Assets over the past three periods came in at $145.2 million, $155.5 million, and $192.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.